HIT Consultant September 4, 2025
What You Should Know:
– Senseonics Holdings, a medical technology company specializing in implantable continuous glucose monitoring (CGM) systems, has announced a Memorandum of Understanding (MOU) with Ascensia Diabetes Care to transition all global commercialization and distribution of its Eversense 365 and future products to Senseonics. Since 2020, Ascensia, a member of PHC Group, has held the exclusive worldwide distribution rights for Eversense products.
This strategic move is set to take effect in the U.S. on January 1, 2026, with Senseonics assuming responsibility for all global sales, marketing, and commercialization. Brian Hansen, who has served as President of CGM at Ascensia, will join Senseonics as Chief Commercial Officer on the same day.
A Strategic Shift for Accelerated Growth
Eversense...
Today's Sponsors
Today's Sponsor